PET for surveillance of lung cancer – pro
PET is not a study appropriate for surveillance. ALthough several studies have raised points to suppport early use of PET for surveillance, guidelines do not support doing so, and there are no hiigh quality studies that find a benefit to it vs CT. Schneider et al ASCO guideline concludes: ” Fluorodeoxyglucose positron emission tomography/computed tomography imaging should not be used as a surveillance tool. “.
Asha Kandathil, PET vs. CT in Lung Cancer Surveillance: The ‘Pro’ Side from the Nuclear Medicine Perspective. https://www.ilcn.org/pet-vs-ct-in-lung-cancer-surveillance-the-pro-side-from-the-nuclear-medicine-perspective/#:~:text=Imaging%20with%2018F%20FDG,on%20surveillance%20chest%20CT%20scan.&text=Increased%20FDG%20uptake%20in%20normal,before%20anatomic%20changes%20on%20CT.,A ccessed 6/14/2024
Lim CH, Park SB, Kim HK, Choi YS, Kim J, Ahn YC, Ahn MJ, Choi JY. Clinical Value of Surveillance 18F-fluorodeoxyglucose PET/CT for Detecting Unsuspected Recurrence or Second Primary Cancer in Non-Small Cell Lung Cancer after Curative Therapy. Cancers (Basel). 2022 Jan 27;14(3):632.
Bryan J. Schneider, MD, Nofisat Ismaila, MD, Joachim Aerts, MD, PhD, Caroline Chiles, MD, Megan E. Daly, MD, Frank C. Detterbeck, MD, Jason W.D. Hearn, MD, SHOW ALL , and Nasser Altorki, MD, Lung Cancer Surveillance After Definitive Curative-Intent Therapy: JCO, ASCO Guideline. December 12, 2019